Mundell, Niamh L.
Sethi, Parneet
Anstey, Kaarin J.
Macpherson, Helen
Dunstan, David W.
Fraser, Steve F.
Daly, Robin M.
Funding for this research was provided by:
ARC Laureate Fellowship (FL190100011)
National Health and Medical Research Council (NHMRC grant 233200, NHMRC grant 233200, NHMRC grant 233200)
NHMRC Senior Research Fellowship (APP1078360)
Article History
Received: 17 August 2021
Accepted: 6 April 2022
First Online: 22 April 2022
Declarations
:
: Written informed consent was obtained from all participants prior to participation. The study was performed in accordance with the Declaration of Helsinki and approved by the International Diabetes Institute (now Baker Heart and Diabetes Institute) Ethics Committee.
: Not applicable.
: The Australian Diabetes, Obesity and Lifestyle study (AusDiab), co-coordinated by the Baker IDI Heart and Diabetes Institute, was supported in part by Abbott Australasia Pty Ltd, Alphapharm Pty Ltd, AstraZeneca, BristolMyers Squibb, Eli Lilly Australia, GlaxoSmithKline, Janssen-Cilag, Merck Sharp & Dohme, Novartis Pharmaceuticals, Novo Nordisk Pharmaceuticals, Pfizer Pty Ltd, Roche Diagnostics Australia, Sanofi Aventis and Sanofi Synthelabo. There are no patents, products in development or marketed products to declare.